# US 2020/0391035 A1 · Stimulation of a nerve supplying the spleen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0391035 A1
- Document ID: US20200391035A1
- Status: Published application
- Kind: A1
- Application number: 16/955,264
- Filed: 2018-12-20
- Published: 2020-12-17
- Earliest claimed: 2017-12-20
- Assignees: Galvani Bioelectronics Limited
- Applicants: Galvani Bioelectronics Limited
- Inventors: MATTEO DONEGA; DANIEL JOHN CHEW; ISHA GUPTA
- Web page: https://patentgrep.com/patent/US20200391035A1

## CPC

- A61N 1/36121: {Production of neurotransmitters; Modulation of genes expression}
- A61B 5/027: using catheters
- A61B 5/416: {the spleen}
- A61N 1/0556: {Cuff electrodes}
- A61N 1/36053: {adapted for vagal stimulation (A61N1/36114 takes precedence)}
- A61N 1/36139: {with automatic adjustment}
- A61N 1/36178: {Burst or pulse train parameters}
- A61B 5/01: Measuring temperature of body parts {; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue} (clinical contact thermometers G01K13/20)
- A61B 5/021: Measuring pressure in heart or blood vessels
- A61B 5/024: Measuring pulse rate or heart rate
- A61B 5/026: Measuring blood flow {(A61B3/1233, A61B3/1241 take precedence)}
- A61B 5/053: Measuring electrical impedance or conductance of a portion of the body
- A61B 5/0816: {Measuring devices for examining respiratory frequency (measuring frequency of electric signals G01R23/00)}
- A61B 5/0836: {Measuring rate of CO2 production}
- A61B 5/087: Measuring breath flow
- A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement}
- A61B 5/14539: {for measuring pH}
- A61B 5/14542: {for measuring blood gases (A61B5/14551 takes precedence)}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Stimulation of neural activity in a nerve supplying the spleen, wherein the nerve is associated with a neurovascular bundle, can modulate pro- and anti-inflammatory molecules levels, thereby reducing inflammation and providing ways of treating inflammatory disorders. The invention provides improved ways of treating inflammatory disorders which minimize off-target effects.

## Claims

### Claim at position 1

1-45. (canceled)

### Claim 46

A system for stimulating the neural activity of a nerve supplying the spleen, wherein the nerve is associated with a neurovascular bundle, the system comprising:
at least one electrode in signaling contact with the nerve; and
at least one controller electrically coupled to the at least one electrode, the at least one controller configured to control the operation of the least one electrode to apply an electrical signal to the nerve, wherein the charge density per phase applied to the nerve by the electrical signal is ≤1100 μC per cm2 per phase.

### Claim 47 (depends on 46)

The system of claim 46 where the charge density per phase is ≤500 μC per cm2 per phase.

### Claim 48 (depends on 46)

The system of claim 46 where the charge density per phase is ≥70 μC per cm2 per phase and ≤500 μC per cm2 per phase.

### Claim 49 (depends on 46)

The system of claim 46 where the charge density per phase is ≤250 μC per cm2 per phase.

### Claim 50 (depends on 46)

The system of claim 46 where the charge density per phase is ≥5 μC per cm2 per phase and ≤180 μC per cm2 per phase.

### Claim 51 (depends on 46)

The system of claim 46 wherein the electrical signal comprises a pulse train comprising a plurality of pulses.

### Claim 52 (depends on 46)

The system of claim 46, wherein the electrical signal produces an improvement in a physiological parameter in the subject, wherein the improvement in the physiological parameter is one or more of the group consisting of: a reduction in pro-inflammatory cytokines, an increase in anti-inflammatory cytokines and/or pro-resolving mediators, an increase in catecholamines, changes in immune cell population or immune cell surface co-stimulatory molecules, a reduction in factors involved in the inflammation cascade, and/or a reduction in immune response mediators.

### Claim 53 (depends on 46)

A method of determining whether a neural interface is correctly placed in signaling contact with a nerve supplying the spleen, wherein the nerve is associated with a neurovascular bundle, the method comprising:
providing the system of claim 46;
positioning the neural interface in signaling contact with the nerve;
controlling the operation of the least one electrode with at least one controller to apply an electrical signal to the nerve;
determining at least one of: blood flow rate in the spleen, blood flow rate in the splenic artery, blood flow rate in the splenic vein, spleen volume, neural activity in the nerve, or impedance of the at least one electrode; and
indicating to an operator that the neural interface had been placed correctly in signaling contact with the nerve.

### Claim 54 (depends on 46)

A method of reversibly stimulating neural activity in a nerve supplying the spleen, wherein the nerve is associated with a neurovascular bundle, the method comprising:
providing the system of claim 46;
positioning at least one electrode in signaling contact with the nerve; and
controlling the operation of the least one electrode with at least one controller to apply an electrical signal to the nerve to stimulate neural activity.

### Claim 55 (depends on 54)

The method of claim 54 wherein the method is for treating inflammatory disorders in a subject.

### Claim 56 (depends on 55)

The method of claim 55 wherein the inflammatory disorder is selected from the group of arthritis, rheumatoid arthritis, osteoarthritis, psoriatic arthritis, Grave's disease, myasthenia gravis, thryoiditis, systemic lupus erythematosus, Goodpasture's syndrome, Behcets's syndrome, allograft rejection, graft-versus-host disease, ankylosing spondylitis, Berger's disease, diabetes including Type I diabetes, Reitier's syndrome, spondyloarthropathy psoriasis, multiple sclerosis, Inflammatory Bowel Disease, Crohn's disease, Addison's disease, autoimmune mediated hair loss, alopecia areata, and ulcerative colitis.

### Claim 57 (depends on 55)

The method of claim 55 wherein the inflammatory disorder is selected from the group of asthma, allergy, anaphylactic shock, immune complex disease, sepsis, septicemia, endotoxic shock, eosinophilic granuloma, granulomatosis, organ ischemia, reperfusion injury, organ necrosis, hay fever, cachexia, hyperexia, septic abortion, HIV infection, herpes infection, organ transplant rejection, disseminated bacteremia, Dengue fever, malaria and sarcoidosis.

### Claim 58 (depends on 55)

The method of claim 55 wherein the inflammatory disorder is an autoimmune disorder.

### Claim 59 (depends on 58)

The method of claim 58 wherein the autoimmune disorder is selected from the group of rheumatoid arthritis, osteoarthritis, psoriatic arthritis, spondyloarthropathy, ankylosing spondylitis, psoriasis, systemic lupus erythematosus (SLE), multiple sclerosis, Inflammatory Bowel Disease, Crohn's disease, and ulcerative colitis and sepsis.

### Claim 60 (depends on 58)

The method of claim 58 wherein the autoimmune disorder is systemic lupus erythematosus (SLE) or rheumatoid arthritis.
